Latest Conference Articles

Speakers at the 2024 International Myeloma Society (IMS) conference share the updates from the myeloma space that they were most excited about this year.

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses improvements in lung function observed in patients enrolled in the BOREAS trial.

Finerenone showed consistent cardiovascular benefits across heart failure populations, with enhanced efficacy in patients with worsening events.

Investigators from Florida Cancer Specialists & Research Institute explored questions surrounding minimal residual disease (MRD) negativity testing in an abstract presented at the International Myeloma Society 21st Annual Meeting & Exposition.

Finerenone is at least as effective in patients who are in the hospital or were recently hospitalized for heart failure as those with stable condition, said Akshay Desai, MD, of Brigham & Women’s Hospital.

As cancer therapies extend patients’ lifespans, it’s important to implement cardioprotective strategies, said Aaron Adkisson, PharmD, of University of Kentucky.

Binod Dhakal, MD, associate professor, division of hematology and oncology, Medical College of Wisconsin and lead investigator of the CARTITUDE-4 study, presented updated data at the 2024 International Myeloma Society conference.

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab for patients with newly diagnosed multiple myeloma.

Ashraf Badros, MB, ChB, professor at the University of Maryland School of Medicine, director of the Multiple Myeloma Service, and vice chair of the Clinical Research Committee for the Program in Oncology, compares the AURIGA trial with other studies on maintenance therapy for patients with multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, myeloma specialist and cellular therapist at Memorial Sloan Kettering Cancer Center, presented the results of the CEPHEUS trial and emphasized the positive impact daratumumab has on patients with multiple myeloma.

An oral session Friday at the International Myeloma Society 21st Annual Meeting & Exposition offered updates for the TRIMM-2 and RedirecTT-1 trials.

Anant Madabhushi, PhD, of Emory University, told attendees at the International Myeloma Society 21st Annual Meeting & Exposition how artificial intelligence's (AI) full potential in cancer care depends on its algorithms being validated by completed clinical trials.

Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, University of Washington, dissects the limited data on T-cell therapies for multiple myeloma, infectious complications, and access to specialized treatment centers.

A new consensus definition for high-risk myeloma patients and promising results from trials dedicated to their care may offer a "paradigm shift" in treatment, experts say at the International Myeloma Society 21st Annual Meeting & Exposition.

Anant Madabhushi, PhD, executive director for the Emory Empathetic AI for Health Institute, proposes AI-based solutions to address health care disparities, emphasizing systemic racism and phenotypic variations.

Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in individual patient management, including decisions about continuing or stopping treatment.

Benjamin Scirica, MD, MPH, director of quality initiatives at Brigham and Women’s Hospital’s Cardiovascular Division, discussed the importance of team-based care and gaps in technology to manage patients at risk of cardiovascular disease (CVD).

April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated approval represents a triumph of science, persistence, and collaboration, said panelists at the International Myeloma Society 21st Annual Meeting & Exposition.

Laurence Sperling, MD, executive director of the Million Hearts initiative at the CDC and CMS, shared insight into population health strategies to address cardiovascular disease (CVD) prevention in at-risk populations.

Daratumumab plus VRd and frontline daratumumab plus VTd produced deep, durable responses in patients with transplant-eligible multiple myeloma in updates to the PERSEUS and CASSIOPEIA trials, respectively.

Speakers on precursor disease addressed distinctions between MGUS and smoldering multiple myeloma, risk stratification, and new thinking on the role of immunological aging, especially how it affects Black patients.

Higher levels of lipoprotein(a) (Lp[a]) were found to be associated with a continuously increasing risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events.

Amy Peterson, MD, professor in the Department of Pediatrics at the University of Wisconsin, discussed current pediatric lipid screening guidelines and the potential evolution of pediatric lipid screening in the coming years.

Multiple sessions at ESMO Congress 2024 covered antibody-drug conjugates (ADCs), which are an emerging therapy that holds great promise in cancer but comes with challenges.

A collection of research by Helen Hobbs, MD, highlights how genetic mutations influence cholesterol levels and impact heart disease risk, offering insights into lifelong cardiovascular health management.

On day 1 of the Family Heart Global Summit, speakers highlighted the critical need for awareness, early diagnosis, and innovative treatment options for familial hypercholesterolemia, sharing significant strides made in the field over the past decade.

The 21st annual meeting of the International Myeloma Society (IMS) takes place September 25-28, 2024, in Rio de Janeiro, Brazil.

The phase 1/2 SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced soft tissue sarcoma.